Drug Trial Radar · NCT01093534
Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
Last checked: Nov 20, 2026Latest source record: Dec 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
547
Actual
Start
Jan 19, 2010
Primary completion
Jun 23, 2011
Study completion Jun 23, 2011
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Mar 26, 2010
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Basic science
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose is to see if solifenacin has any effect on bladder wall thickness and urine inflammatory marker measurements after 12 weeks of treatment.
Conditions
- Detrusor Overactivity
- Overactive Bladder
Interventions
PlaceboDrug
Matching solifenacin placebo tablet
solifenacinDrug
Tablet for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 12 in Bladder Wall ThicknessTime frame: Baseline and Week 12
- Neutralized Urinary Nerve Growth Factor Normalized by Urine Creatinine at Week 12Time frame: Week 12
Locations
79 sites in 20 countries. Site status is shown where the registry gives one.
Site not named
New York, New York
Site not named
New York, New York
Site not named
West Reading, Pennsylvania
Site not named
Graz, Austria
Site not named
Linz, Austria
Site not named
Linz, Austria
Site not named
Edegem, Belgium
Site not named
Ghent, Belgium
Site not named
Kortrijk, Belgium
Site not named
Sofia, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Varba, Bulgaria
Site not named
Victoria, British Columbia, Canada
Site not named
Victoria, British Columbia, Canada
Site not named
Barrie, Ontario, Canada
Site not named
Brampton, Ontario, Canada
Site not named
Brantford, Ontario, Canada
Site not named
Kitchener, Ontario, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Sherbrooke, Quebec, Canada
Site not named
Brno, Czechia
Site not named
Hradec Králové, Czechia
Site not named
Podolí, Czechia
Site not named
Marseille, France
Site not named
Paris, France
Site not named
Aachen, Germany
Site not named
Berlin, Germany
Site not named
Hanover, Germany
Site not named
Munich, Germany
Site not named
Budapest, Hungary
Site not named
Budapest, Hungary
Site not named
Szeged, Hungary
Site not named
Székesfehérvár, Hungary
Site not named
Haifa, Israel
Site not named
Petah Tikva, Israel
Site not named
Ramat Gan, Israel
Site not named
Avellino, Italy
Site not named
Milan, Italy
Site not named
Milan, Italy
Site not named
Rome, Italy
Showing 40 of 79 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.